M A Socinski

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. request reprint
    Socinski M, Morris D, Masters G, Lilenbaum R. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest. 2003;123:226S-243S pubmed
    ..In addition, this awareness will allow them to make referrals, when appropriate, to physicians who are trained in the administration of chemotherapy and the management of patients undergoing such therapy. ..
  2. request reprint
    Socinski M, Bogart J. Limited-stage small-cell lung cancer: the current status of combined-modality therapy. J Clin Oncol. 2007;25:4137-45 pubmed
    ..LS-SCLC has been a model cancer in terms of the potential benefit of combined chemoradiotherapy strategies in improving patient outcomes. ..
  3. request reprint
    Socinski M, Manikhas G, Stroyakovsky D, Makhson A, Cheporov S, Orlov S, et al. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2010;5:852-61 pubmed
    ..Based on favorable efficacy and safety profiles, a phase 3, randomized, multicenter study comparing 100 mg/m(2) weekly nab-paclitaxel plus q3w carboplatin to solvent-based paclitaxel plus carboplatin has enrolled patients. ..
  4. Socinski M, Blackstock A, Bogart J, Wang X, Munley M, Rosenman J, et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol. 2008;26:2457-63 pubmed publisher
    ..Arm A reached the primary end point with an estimated MST longer than 18 months and will be compared with a standard dose of TRT in a planned randomized phase III trial in the United States cooperative groups. ..
  5. Socinski M, Scappaticci F, Samant M, Kolb M, Kozloff M. Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer. J Thorac Oncol. 2010;5:354-60 pubmed publisher
    ..The addition of S to PCB was not well tolerated because of toxicities. This combination should not be studied further at these doses and schedules. ..
  6. request reprint
    Socinski M. Irinotecan in non-small-cell lung cancer: status of ongoing trials. Clin Lung Cancer. 2002;4 Suppl 1:S15-20 pubmed
    ..Future trials should focus on the integration of the new targeted agents in combination with irinotecan-containing regimens in all stages of NSCLC...
  7. request reprint
    Socinski M, Rivera M, Detterbeck F. Gemcitabine-based combinations as preoperative therapy in resectable non-small-cell lung cancer. Clin Lung Cancer. 2003;4 Suppl 2:S50-5 pubmed
    ..Continued evaluation of gemcitabine-containing regimens as preoperative therapy is warranted given their level of activity and tolerability in advanced NSCLC...
  8. request reprint
    Socinski M, Sandler A, Miller L, Locker P, Hanover C, Elfring G, et al. Irinotecan (CPT-11) in triplet combinations in patients with advanced non small-cell lung cancer: a review and report of a phase I/II trial. Clin Lung Cancer. 2001;2 Suppl 2:S26-33 pubmed
    ..The combination shows appreciable activity, and survival data are favorable, warranting further study of this regimen. A review of other irinotecan-containing triplet combinations is presented...